Navigation Links
Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2
Date:9/30/2013

SAN DIEGO, Sept. 30, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Leerink Swann Rare Disease Roundtable, on Wednesday, October 2nd, 2013 at 3:00 p.m. Eastern time at Le Parker Meridien Hotel in New York City.

Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014.  More information can be found on the Company's web site at www.masttherapeutics.com.

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188 in acute limb ischemia, including the timing of initiation of the planned phase 2 study.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
3. PTC Therapeutics to Present at World Muscle Society Congress
4. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
5. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
6. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
7. Cell Therapeutics Announces Closing of Sale of Convertible Preferred Stock
8. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
9. Cell Therapeutics Announces Sale of Convertible Preferred Stock
10. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
11. Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... ... , ... Over 60 schools in the northwest panhandle of Florida began the ... to provide virtual mental health care to more than 35,000 students still affected by ... 2018 [1]. , “This initiative by the state of Florida,” says Choice Business Connections ...
(Date:11/11/2019)... , ... November 11, 2019 ... ... rapidly growing drug class and have a major impact in the oncology ... challenges still need to be overcome. Among these, defining valuable and adapted ...
(Date:11/9/2019)... ... November 08, 2019 , ... As part of Pulmonary Hypertension ... day to help raise awareness and improve diagnosis of a rare form of ... of PH, CTEPH has several treatment options, including a potentially curative surgery. , ...
Breaking Medicine Technology:
(Date:11/11/2019)... , ... November 11, 2019 , ... ... called for improved foodborne illness prevention and urges increased adoption of compliance technology ... a series of vegetable products sold to select retailers in the United States ...
(Date:11/9/2019)... ... November 08, 2019 , ... Pennsylvania College of Health ... announce that after the fourth quarter of the 2018-2019 academic year, the school’s ... pass rate. The College’s annual pass rate for the 2018-2019 academic year was ...
(Date:11/7/2019)... LOS ANGELES (PRWEB) , ... November 06, 2019 , ... ... rate of obesity in the United States. According to the article, while no U.S. ... have a population that is over 20 percent obese. The article cites quite a ...
(Date:11/7/2019)... ... November 07, 2019 , ... “We are very excited to announce that the Medical Spa ... row,” says AmSpa CEO and Founder, Alex Thiersch, JD. “Every year, we have expanded the ... the medical spa industry, and to provide the best options for attendees, and this year ...
(Date:11/6/2019)... ... November 06, 2019 , ... ValidCare, the ... Kentucky Research Foundation (UKRF) today announced they have entered into a services agreement ... companies access to the broad resources of each organization to conduct clinical and/or ...
Breaking Medicine News(10 mins):